1887

Abstract

Serological tests for COVID-19 are important in providing results for surveillance and supporting diagnosis. Investigating the serological response in COVID-19 patients with different disease severity is important for assessing the clinical utility of serological assays.

However, few studies have investigated the clinical utility of antibody assays for COVID-19 or differences in antibody response in association with disease severity.

The study aimed to evaluate the clinical characteristics and clinical utility of VITROS SARS-CoV-2 antibody tests according to COVID-19 severity in patients in Japan.

We analysed 255 serum specimens from 130 COVID-19 patients and examined clinical records and laboratory data. Presence of total (IgA, IgM, and IgG) and specific IgG antibody for the spike 1 antigen of SARS-CoV-2 was determined using VITROS Anti-SARS-CoV-2 antibody tests.

Overall, 98 (75.4 %) and 32 (24.6 %) patients had mild and severe COVID-19, respectively. On admission, 76 (58.5 %) and 45 (34.6 %) patients were positive for total and IgG antibody assays. Among 91 patients at discharge, 90 (98.9 %) and 81 (89.0 %) were positive for total and IgG antibody, respectively. Clinical background and laboratory findings on admission, but not the prevalence or concentration of total or IgG antibody, were associated with disease prognosis. Total and IgG antibody intensities were significantly higher in severe cases than in mild cases in serum collected >11 days after onset, but not within 10 days.

VITROS Anti-SARS-CoV-2 total and IgG assays will be useful as supporting diagnostic and surveillance tools and for evaluation of humoral immune response to COVID-19. Optimal prediction of disease prognosis is made from considering both clinical history and laboratory findings.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001291
2021-04-16
2021-05-15
Loading full text...

Full text loading...

/deliver/fulltext/jmm/70/4/jmm001291.html?itemId=/content/journal/jmm/10.1099/jmm.0.001291&mimeType=html&fmt=ahah

References

  1. Huang C, Wang Y, Li X, Ren L, Zhao J et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506 [CrossRef][PubMed]
    [Google Scholar]
  2. Winter AK, Hegde ST. The important role of serology for COVID-19 control. Lancet Infect Dis 2020; 20:758–759 [CrossRef][PubMed]
    [Google Scholar]
  3. Shen L, Wang C, Zhao J, Tang X, Shen Y et al. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. Emerg Microbes Infect 2020; 9:1096–1101 [CrossRef][PubMed]
    [Google Scholar]
  4. Sun B, Feng Y, Mo X, Zheng P, Wang Q et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect 2020; 9:940–948 [CrossRef][PubMed]
    [Google Scholar]
  5. Qu J, Wu C, Li X, Zhang G, Jiang Z et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71:2255–2258 [CrossRef][PubMed]
    [Google Scholar]
  6. Xie J, Ding C, Li J, Wang Y, Guo H et al. Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test. J Med Virol 2020; 92:2004–2010 [CrossRef][PubMed]
    [Google Scholar]
  7. Hou H, Wang T, Zhang B, Luo Y, Mao L et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunology 2020; 9:e01136 [CrossRef][PubMed]
    [Google Scholar]
  8. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020; 20:565–574 [CrossRef][PubMed]
    [Google Scholar]
  9. Perera RA, Mok CK, Tsang OT, Lv H, Ko RL et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill 2020; 25:2000421 [CrossRef][PubMed]
    [Google Scholar]
  10. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis 2020; 26:1478–1488 [CrossRef][PubMed]
    [Google Scholar]
  11. Yong SEF, Anderson DE, Wei WE, Pang J, Chia WN et al. Connecting clusters of COVID-19: an epidemiological and serological investigation. Lancet Infect Dis 2020; 20:809–815 [CrossRef][PubMed]
    [Google Scholar]
  12. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C et al. Performance characteristics of the Abbott architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol 2020; 58:e00941–20 [CrossRef][PubMed]
    [Google Scholar]
  13. Pan Y, Li X, Yang G, Fan J, Tang Y et al. Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infect 2020; 81:e28–e32 [CrossRef][PubMed]
    [Google Scholar]
  14. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. J Clin Virol 2020; 129:104480 [CrossRef][PubMed]
    [Google Scholar]
  15. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 181:281–292 [CrossRef][PubMed]
    [Google Scholar]
  16. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol 2020; 5:eabc8413 [CrossRef][PubMed]
    [Google Scholar]
  17. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med 2020; 26:1033–1036 [CrossRef][PubMed]
    [Google Scholar]
  18. Murrell I, Forde D, Tyson L, Chichester L, Garratt A et al. A longitudinal comparison of spike and nucleocapsid SARS-CoV-2 antibody responses in a tertiary hospital’s laboratory workers with validation of DBS specimen analysis. medRxiv 2020; 2020.10.29.20219931:
    [Google Scholar]
  19. Theel ES, Harring J, Hilgart H, Granger D. Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2. J Clin Microbiol 2020; 58:e01243–20 [CrossRef]
    [Google Scholar]
  20. Public Health England COVID-19: laboratory evaluations of serological assays. https://www.gov.uk/government/publications/covid-19-laboratory-evaluations-of-serological-assays 20 January 2021
  21. Shirato K, Nao N, Katano H, Takayama I, Saito S et al. Development of genetic diagnostic methods for detection for novel coronavirus 2019(nCoV-2019) in Japan. Jpn J Infect Dis 2020; 73:304–307 [CrossRef][PubMed]
    [Google Scholar]
  22. Zhao J, Yuan Q, Wang H, Liu W, Liao X et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis 2020; 71:2027–2034 [CrossRef][PubMed]
    [Google Scholar]
  23. Liu W, Liu L, Kou G, Zheng Y, Ding Y et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J Clin Microbiol 2020; 58:e00461–20 [CrossRef][PubMed]
    [Google Scholar]
  24. Nicol T, Lefeuvre C, Serri O, Pivert A, Joubaud F et al. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG biotech). J Clin Virol 2020; 129:104511 [CrossRef][PubMed]
    [Google Scholar]
  25. Theel ES, Harring J, Hilgart H, Granger D. Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2. J Clin Microbiol 2020; 58:e01243–20 [CrossRef][PubMed]
    [Google Scholar]
  26. Egger M, Bundschuh C, Wiesinger K, Gabriel C, Clodi M et al. Comparison of the Elecsys anti-SARS-CoV-2 immunoassay with the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma. Clin Chim Acta 2020; 509:18–21 [CrossRef][PubMed]
    [Google Scholar]
  27. Ozturk T, Howell C, Benameur K, Ramonell RP, Cashman K et al. Cross-Sectional IgM and IgG profiles in SARS-CoV-2 infection. medRxiv 2020; 2020.05.10.20097535:2020.05.10.20097535 14 May 2020 [CrossRef][PubMed]
    [Google Scholar]
  28. Liu T, Hsiung J, Zhao S, Kost J, Sreedhar D et al. High-accuracy multiplexed SARS-CoV-2 antibody assay with avidity and saliva capability on a Nano-Plasmonic platform. bioRxiv 2020; 155580:
    [Google Scholar]
  29. Liu J, Liu Y, Xiang P, Pu L, Xiong H et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 2020; 18:206 [CrossRef][PubMed]
    [Google Scholar]
  30. Zhou F, Yu T, Du R, Fan G, Liu Y et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–1062 [CrossRef][PubMed]
    [Google Scholar]
  31. Tabata S, Imai K, Kawano S, Ikeda M, Kodama T et al. Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the diamond Princess cruise SHIP: a retrospective analysis. Lancet Infect Dis 2020; 20:1043–1050 [CrossRef][PubMed]
    [Google Scholar]
  32. Li X, Xu S, Yu M, Wang K, Tao Y et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020; 146:110–118 [CrossRef][PubMed]
    [Google Scholar]
  33. Wang Y, Shi L, Wang Y, Yang H. An updated meta-analysis of AST and ALT levels and the mortality of COVID-19 patients. Am J Emerg Med 2021; 40:208–209 [CrossRef][PubMed]
    [Google Scholar]
  34. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26:1200–1204 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001291
Loading
/content/journal/jmm/10.1099/jmm.0.001291
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error